Measuring Immune Response and Cytokine Autoantibodies in Human Sepsis Samples
Dr. Amy Johnson | Immunoassay Platform Solutions Specialist
A biochemist by training, Amy received her PhD, and completed her postdoctoral training, at the University of North Carolina at Chapel Hill where she used cell culture and rodent models, as well as human populations, to study the effects of aberrant micro- and macro-nutrient metabolism on human health. Amy joined the Immunoassay Specialist team at MilliporeSigma in 2016, where she supports protein/biomarker discovery researchers, as well as bioanalytical groups.
The MILLIPLEX®Human Cytokine/Chemokine/Growth Factor Panel A (Cat. No. HCYTA-60K) features an exciting new large combination of 48 configurable human cytokine, chemokine and growth factor assays requiring only 25 µL of each sample. Representative data shown here exemplifies the value of this kit for the study of relevant disease sample biomarkers in serum and plasma biofluids.
This study demonstrates the value of using multiplex technology to evaluate multiple autoantibodies, in this case with the MILLIPLEX®Human Cytokine Autoantibody Panel (Cat. No. HCYTAAB-17K) allowing for an extensive autoantibody profile to evaluate patients with autoimmune or infectious disease. Anti-cytokine autoantibodies may have an activating or neutralizing affect and can aid in monitoring disease activity.
The use of these two types of capture methods exemplifies the flexibility of the Luminex®platform, and the power of analyzing multiple analytes.